Compare Nu Holdings Ltd (NU) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nu Holdings Ltd vs Twist Bioscience Corp — how do they compare? Nu Holdings Ltd trades at $15.46 (market cap $75.26B), while Twist Bioscience Corp trades at $157 (market cap $10.32B). The key difference: Nu Holdings Ltd is far larger — about 7.3× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Nu Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nu Holdings Ltd for 53 Days and Twist Bioscience Corp for 27 Days on average.
| NU | TWST | |
|---|---|---|
Market Cap | $75.26B | $10.32B |
Volume | 82,363,718 | 5,894,998 |
Sector | Financials | Health |
52-Week High | $18.76 | $205.00 |
52-Week Low | $11.60 | $25.45 |
Typical Hold Time | 53 Days | 27 Days |
Enterprise Value | $97.88B | $10.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NU Holdings (NU) trades at $15.58, down 0.51% on the day, as the Brazilian digital bank navigates market volatility. The stock shows strong fundamental momentum with revenue growing from $3.0B in 2022 to $10.6B in 2025 and net income turning positive to $2.9B. Technical indicators are mixed with a bullish moving average signal but overbought RSI conditions. Recent news highlights acquisition speculation and Goldman Sachs' bullish $19 price target.
NU presents a compelling growth story with expanding profitability and analyst support, though risks include credit concentration and acquisition uncertainty. The stock trades near consensus targets with 57% buy ratings, suggesting moderate upside potential if execution continues.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
